Name | 3-O-ethyl 5-O-(2-piperidin-1-ylethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
---|---|
Synonyms |
Epddnp
YS 201 YS-201 |
Description | YS-201 is a dihydropyridine-type calcium channel antagonist previously in clinical trials for the treatment of angina pectoris and hypertension. |
---|---|
Related Catalog | |
In Vivo | YS-201 (Diperdipine) markedly reduces systemic vascular resistance and improves stroke index and left ventricular ejection fraction. Mean pulmonary artery and wedge pressures are slightly increased as a possible consequence of enhanced venous return, whereas right atrial and left ventricular end-diastolic pressures are not significantly changed. Nevertheless, an increase in preload is clearly indicated by an augmented left ventricular end-diastolic volume index after administration of diperdipine[1]. After intravenous and oral doses, absolute bioavailability is calculated to be 18.7%. Biliaryexcretion accounts for about 0.1% of the total clearance of diperdipine and does not contribute to the overall elimination of the drug. After intraportal administration, the bioavailable fraction of diperdipine is increasing up to 44.3% suggesting a prehepatic site of loss of the drug[2]. The single application of diperdipine to mice and rats by gavage causes intolerance reactions starting at the lowest tested dose level of 200 mg/kg b.w. p.o. (mice) and at 250 mg/kg b.w. p.o. (rats). In the rat, toxic effects occur from 15 mg diperdipine/kg b.w./day p.o. onwards[3]. |
References |
Density | 1.207g/cm3 |
---|---|
Boiling Point | 593.9ºC at 760 mmHg |
Molecular Formula | C24H31N3O6 |
Molecular Weight | 457.51900 |
Flash Point | 313ºC |
Exact Mass | 457.22100 |
PSA | 113.69000 |
LogP | 4.21170 |
Vapour Pressure | 4.47E-14mmHg at 25°C |
Index of Refraction | 1.556 |
Storage condition | 2-8℃ |